With Kathy High on board, AskBio makes next lead­er­ship play and se­lects Bay­er's Gu­ru Ra­ma­murthy as fi­nance chief; Myles O'Neill and Melis­sa Barnes set to re­tire from Eli Lil­ly

→ The stars aligned to bring in Kathy High as pres­i­dent of ther­a­peu­tics, and Brain Neu­rother­a­py Bio founder Krystof Bankiewicz now leads its Parkin­son’s pro­gram. And in its first big lead­er­ship move since they signed on to the team, gene ther­a­py play­er AskBio has ap­point­ed Gu­ru Ra­ma­murthy CFO, a spokesper­son tells End­points News. Six months re­moved from strik­ing a deal to ac­quire AskBio, it should come as no sur­prise that Ra­ma­murthy is a 20-year Bay­er alum: More re­cent­ly he had been the Ger­man multi­na­tion­al’s glob­al fi­nance lead for the on­col­o­gy fran­chise, and pri­or to that, Ra­ma­murthy was CFO of the North Amer­i­can busi­ness at Bay­er Con­sumer Health.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN